Advanced search
Publication Cover
Journal of Psychoactive Drugs Volume 49, 2017 - Issue 3
Submit an article Journal homepage
1,153
Views
15
CrossRef citations to date
0
Altmetric
Articles

Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences

Annamarie HeinkDoctoral Candidate, School of Professional Psychology, Spalding University, Louisville, KY, USACorrespondence[email protected]
, M.A.,
Steve KatsikasChair, School of Professional Psychology, Spalding University, Louisville, KY, USA
, Ph.D. &
Tiffany Lange-AltmanPTSD/SUD Psychologist, Hampton Veteran Affairs, School of Professional Psychology, Spalding University, Louisville, KY, USA
, Psy.D.
Pages 201-208 | Received 03 Jul 2016, Accepted 29 Dec 2016, Published online: 07 Mar 2017

References

  • Alper, K. R. 2001. Ibogaine: A review. The Alkaloids 56:1–38.
  • Alper, K. R., D. Beal, and C. D. Kaplan. 2001. A contemporary history of ibogaine in the United States and Europe. The Alkaloids 56:249–81.
  • Alper, K. R., H. S. Lotsof, and C. D. Kaplan. 2008. The ibogaine medical subculture. Journal of Ethnopharmacology 115:9–24. doi:10.1016/j.jep.2007.08.034.
  • Bastiaans, E. 2004. Life after ibogaine: An exploratory study of the long-term effects of ibogaine treatment on drug addicts. Unpublished science internship report, Vrije University, Amsterdam, Netherlands.
  • Carnicella, S., D. He, Q. Yowell, S. Glick, and D. Ron. 2010. Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addiction Biology 15 (4):424–33. doi:10.1111/adb.2010.15.issue-4.
  • Dittrich, A. 1998. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31 (2):80–84. doi:10.1055/s-2007-979351.
  • Dittrich, A., D. Lamparter, and M. Maurer. 2011. 5D-ASC: Questionnaire for the assessment of altered states of consciousness: A short introduction. Zurich, Switzerland: PSIN PLUS Publicationes.
  • Dittrich, A., S. von Arx, and S. Staub. 1985. International study on altered states of consciousness (ISAAC): Summary of results. German Journal of Psychology 9:319–39.
  • Holford, N. H. G., and L. B. Sheiner. 1981. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics 6:429–53. doi:10.2165/00003088-198106060-00002.
  • Ibogaine University. 2013. Ibogaine treatment cost. http://www.ibogaineuniversity.com/ibogaine-treatment-cost/.
  • KBF. 2009. A psycho-spiritual experience: Experience with ibogaine (ID 76892). erowid.org/exp/76892.
  • Koenig, X., M. Kovar, L. Rubi, A. K. Mike, P. Lukacs, V. S. Gawali, H. Todt, K. Hilber, and W. Sandtner. 2013. Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug’s cardiac ion channel profile. Toxicology and Applied Pharmacology 273 (2):259–68. doi:10.1016/j.taap.2013.05.012.
  • Kotler, S. 2010. Fighting drugs with drugs: An obscure hallucinogen gains legitimacy as a solution for additions. Popular Science. http://www.popsci.com/science/article/2010-07/fighting-drugs-drugs ( accessed July 21, 2015).
  • Lawson, G. 1982. Relation of counselor traits to evaluation of the counseling relationship by alcoholics. Journal of Studies on Alcohol 43 (7):834–39. doi:10.15288/jsa.1982.43.834.
  • Levi, M. S., and R. F. Borne. 2002. A review of chemical agents in the pharmacotherapy of addiction. Current Medicinal Chemistry 9 (20):1807–18. doi:10.2174/0929867023368980.
  • Lotsof, H., and B. Wachtel. 2003. Manual for ibogaine therapy: Screening, safety, monitoring, and aftercare (2nd revision). http://www.ibogaine.org/manual.html.
  • Lotsof, H. S. 1994. Ibogaine in the treatment of chemical dependence disorders: Clinical perspectives. Maps (V) 3:16–27. http://www.ibogaine.org/clin-perspectives.html.
  • Maas, U., and S. Strubelt. 2006. Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Medical Hypotheses 67:960–64. doi:10.1016/j.mehy.2006.02.050.
  • Mash, D. C., C. A. Kovera, B. E. Buck, M. D. Norenberg, P. Shapshak, W. L. Hearn, and J. Sanchez-Ramos. 1998. Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences 844:274–92.
  • Mash, D. C., C. A. Kovera, J. Pablo, R. F. Tyndale, F. D. Ervin, I. C. Williams, … M. Mayor. 2000. Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences 914:394–401. doi:10.1111/j.1749-6632.2000.tb05213.x.
  • Multidisciplinary Association for Psychedelic Studies (MAPS). 2003. Ibogaine: Treatment outcomes and observations. Maps xiii(2):16–21. http://www.maps.org/news-letters/v13n2/v13n2_16-21.pdf.
  • Naranjo, C. C. 1974. Ibogaine: Fantasy and reality. The Healing Journey. http://www.ibogaine.desk.nl/naranjo.html.
  • Pinchbeck, D. 2002. Breaking open the head: A psychedelic journey into the heart of contemporary shamanism. New York, NY: Broadway Books.
  • Siegel, S., J. A. Kim, L. Weise-Kelly, and L. A. Parker. 1996. Effect of ibogaine on the development of tolerance to the analgesic effect of morphine. Experimental and Clinical Psychopharmacology 4 (3):258–63. doi:10.1037/1064-1297.4.3.258.
  • Studerus, E. 2012. Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness. Ph.D. thesis, University of Zurich, Zurich, Switzerland.
  • Studerus, E., A. Gamma, and F. Vollenweider. 2010. Psychometric evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE 5 (8):1–19. https://protect-us.mimecast.com/s/rx4mBRUAY4Qbca3Adoi%2F10.1371%Fjournal.pone.0012412
  • Wikler, A. 1948. Recent progress in research on the neurophysiologic basis of morphine addiction. American Journal of Psychiatry 105:329–38. doi:10.1176/ajp.105.5.329.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.